Viral, bacterial or both? Regardless, we need to treat infection in copd

European Respiratory Journal

Volumn 44, Issue 1, 2014, Pages 11-12

  Welte, Tobias ^a,b   Miravitlles, Marc ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Centre for Lung Research   (Germany)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID;

BACTERIAL INFECTION; BACTERIAL LOAD; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; HOST PATHOGEN INTERACTION; HUMAN; INFLUENZA VIRUS; MICROBIAL COLONIZATION; MORTALITY; NONHUMAN; ORGANISMAL INTERACTION; PHENOTYPE; PICORNAVIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHINOVIRUS; RISK ASSESSMENT; SPUTUM ANALYSIS; SYMPTOMATOLOGY; TREATMENT INDICATION; VIRUS INFECTION; VIRUS LOAD; COMPLICATION; FEMALE; MALE; PICORNAVIRUS INFECTION;

FEMALE; HUMANS; MALE; PICORNAVIRIDAE INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RHINOVIRUS;

EID: 84903836832     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00041914     Document Type: Review

References (30)

1. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
2. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67: 1075-1080.
3. Singh S, Amin AV, Loke YK. Long-term use of inhale corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch Intern Med 2009; 169: 219-229.
4. Kim JH, Park JS, Kim KH, et al. Inhaled corticosteroid is associated with an incerased risk of TB in patients with COPD. Chest 2013; 143: 1018-1024.
5. Miravitlles M, Moragas A, Hernández S, et al. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment. Chest 2013; 144: 1571-1577.
6. Miravitlles M, Kruesmann F, Haverstock D, et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J 2012; 39: 1354-1360.
7. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
8. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
9. Wilkinson TMA, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1090-1095.
10. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395.
11. Martínez-García MA, De la Rosa Carrillo D, Soler-Catalunã JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823-831.
12. Renom F, Yáñez A, Garau M, et al. Prognosis of COPD patients requiring frequent hospitalization: Role of airway infection. Respir Med 2010; 104: 840-848.
13. Matkovic Z, Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype. Respir Med 2013; 107: 10-22.
14. George SN, Garcha DS, MacKay AJ, et al. Human rhinovirus infection during naturally-occurring COPD exacerbations. Eur Respir J 2014; 44: 87-96.
15. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-1320.
16. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288-295.
17. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important. Eur Respir J 2002; 20: Suppl., 9s-19s.
18. Mohan A, Chandra S, Agarwal D, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: A systematic review. Respirology 2010; 15: 536-542.
19. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit CareMed 2001; 164: 1618-1623.
20. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121.
21. Wilkinson TMA, Hurst JR, Perera WR, et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006; 129: 317-324.
22. Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011; 183: 734-742.
23. Oliver BGG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax 2008; 63: 519-525.
24. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after Rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1224-1231.
25. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
26. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 554-564.
27. Matkovic Z, Huerta A, Soler N, et al. Predictors of adverse outcome in patients hospitalised for exacerbation of COPD. Respiration 2012; 84: 17-26.
28. Wilkinson TMSA, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303.
29. Hurst JR, Donaldson GC, Wilkinson TMA, et al. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 2005; 26: 846-852.
30. Miravitlles M, Soler-Catalunã JJ, Calle M, et al. Treatment of COPD by clinical phenotypes. Putting old evidence into clinical practice. Eur Respir J 2013; 41: 1252-1256.